co-administration of 4-1bb agonist antibody converts a therapeutic hpv e6/e7 vaccine into a curative...
TRANSCRIPT
Co-administration of 4-1BB agonist antibody converts a
therapeutic HPV E6/E7 vaccine into a curative therapy
Michael A. Curran, Ph.D.MD Anderson Cancer CenterDepartment of Immunology
I have research collaborations with Bristol Myers Squibb, Astrazeneca, Adimab, and Threshold.
I receive royalties from the patent “Methods and Compositions for Localized Secretion of anti-CTLA-4
Antibodies”.
I will be talking about investigational therapeutics.
HPV Induced Cancers HPV E6/E7 oncoproteins are
causative for cervical, vulvar, vaginal, penile, anal, and oropharyngeal cancers
Each year ~20,000 HPV-driven cancers occur in women with cervical cancer the most common
Each year ~12,000 HPV-driven cancers occur in men with oropharyngeal cancer most common
As immunologically foreign proteins which are critical for maintenance of the transformed phenotype, E6 and E7 are ideal vaccine targets.
Responses to specific E6/E7 peptides predict recurrence-free
survival in HPV
0
20
40
60
80
100
120
Q15L Q19D Q15L Q19D
Recurrence-free With recurrence
% P
os
itiv
e p
op
ula
tio
n
IFN-g IL-12 IL-4 IL-10
0
20
40
60
80
100
Co
ntr
ol
(H
PV
-/C
IN-)
Un
tre
ate
d
(HP
V+
CIN
+)
Tre
ate
d
(Re
cu
rre
nc
e-)
Tre
ate
d
(Re
cu
rre
nc
e+)
% P
op
ula
tio
n w
ith
po
sit
ive
H
PV
-sp
eci
fic
imm
un
ity
E6 Peptides E7 Peptides
• E6 peptide: – Q15L (43-57) QLLRREVYDFAFRDL
• E7 peptide:– Q19D (44-62) QAEPDRAHYNIVTFCCKCD
Shailbala Singh
An intra-nasal HPV E6/E7 : α-GalCer vaccine slows growth of
TC-1 tumors
Shailbala Singh
4-1BB agonist antibody and HPV E6/E7 vaccine synergize in curing
TC-1 tumors
Todd Bartkowiak, M.S.
Diverse adjuvant effects of checkpoint blockade with HPV
vaccination
Todd Bartkowiak, M.S.
Intra-tumoral CD8/Treg ratios are dramatically elevated in Vax + α4-
1BB group
Todd Bartkowiak, M.S.
Enhanced CD8/Treg ratios result from both decreased Treg and
increased CD8 T cells
Todd Bartkowiak, M.S.
Vax + α4-1BB promotes high density tumor infiltration by E7-
specific CD8 T cells
Todd Bartkowiak, M.S.
Both HPV Vax/adjuvant and α4-1BB contribute to enhanced tumor
T cell response
Todd Bartkowiak, M.S.
4-1BB agonist antibodies also activate APCs helping to
generate ThEO/TcEO T cells
Spleen ThEO T Cells
Tumor ThEO T Cells
Curran M A et al. J Exp Med 2013;210:743-755
Highly cytotoxic ThEO/TcEO phenotype T cells are abundant in
tumors of α4-1BB treated mice
Vaccine + α4-1BB regresses tumors established in the mucosa of the female
reproductive tractDay 6 Day 15 Day 19
PBS
Vaccine
Vaccine+ α-4-1BB
Vaccine+ α-CTLA4
Regression of TC-1 tumors in FRT
Shailbala Singh
4-1BB agonist antibody vaccine amplification : a paradigm for
therapeutic vaccines? Outside of HPV E6/E7, current
therapeutic vaccination trials include Her2, Muc1, NY-ESO, hTERT, Survivin, PAP, PSA, Mesothelin, et. al.
Future studies will seek to confirm whether the advantages of 4-1BB agonist antibody as a vaccine potentiator are specific to HPV E6/E7 or are consistent across the therapeutic cancer vaccination landscape.
Acknowledgements
Curran Lab:
Michael A. Curran
Todd Bartkowiak
Casey Ager
Midan Ai
Pratha Budhani
Ashvin Jaiswal
Beata Kaplan-Lerman
Jie Sheng
Sastry Lab:
K. Jagannadha Sastry
Shailbala Singh
Guojun Yang
James P. Allison